[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
Primary central nervous system (CNS) lymphomas represent 5% of primary brain tumors. More
than 90% of them are diffuse large B-cell lymphomas.
[18F]-Fluorodeoxyglucose positron emission tomography (PET-[18F]-FDG) is the gold standard
for imaging systemic lymphomas, but its application in primary CNS lymphoma is compromised by
the limited specificity of brain fixations and the high uptake of [18F]-FDG in healthy brain
tissue.
[18F]-Fludarabine is a new radiopharmaceutical developed for PET imaging of lymphomas.
Preclinical studies indicate a restricted binding specificity to lymphoid tissue compared to
[18F]-FDG and an ability to detect residual lymphoma disease after treatment. A pilot study
in humans shows good agreement of its binding with tumor sites in systemic lymphoma and
superior tumor contrast to [18F]-FDG. Finally, a recent preclinical study shows a binding
ratio in brain lymphoma 3 times higher than that of healthy brain tissue in mouse models of
primary CNS lymphoma, whereas in mouse models of high-grade glial tumors, the binding level
is very low, comparable to that of healthy tissue (background). Investigators hypothesize
that [18F]-Fludarabine could be the radiopharmaceutical of choice for the diagnosis and
monitoring of primary CNS lymphomas in PET.
The main objective of the study is to characterize the cerebral distribution and
[18F]-Fludarabine uptake in newly-diagnosed primary CNS lymphomas before surgery,
chemotherapy or radiotherapy, using PET-MR imaging.